Corporate Report

The report sets out KAKEN's FY2020 value-creation model and five priority issues covering medical solutions, pharmaceutical responsibilities, governance, the environment and fulfilling workplaces. It highlights approval and the November 2020 launch of Ecclock Gel 5%, Japan's first topical treatment for primary axillary hyperhidrosis. Consolidated net sales were ¥74,979 million, while CO2 emissions were 20,605 t-CO2.